News - Page 7 of 13 - Leukaemia Care

2nd September 2021

Leukaemia Care and OPAAL team up for Blood Cancer Awareness Month

We've teamed up with the Older People's Advocacy Alliance (OPAAL) to raise awareness of leukaemia in the 65+ community. Find out more about our collaboration.

18th August 2021

Leukaemia Care and the UK Mastocytosis Support Group successfully campaign for patients with very rare condition to access new treatment

The National Institute for Health and Care Excellence (NICE) have made recommendations for midostaurin to become an NHS treatment option for advanced systemic mastocytosis (AdvSM) patients in England. This decision follows a 4  year  long campaign by Leukaemia Care, The UK Mastocytosis Support Group and affected patients. 

12th August 2021

Leukaemia Care takes steps to show support for the LGBTQ+ community

To show the charity's support for the LGBTQ+ community, Leukaemia Care have taken the decision to include staff members' pronouns in their email signatures. Find out more about this decision here.

14th July 2021

Many leukaemia patients face a devastating choice as ‘Freedom Day’ looms: their life or their livelihood?

“Many people living with leukaemia feel they have been forgotten about in the rush to ease COVID-19 restrictions." Here, you can find out what we are doing to help support clinically extremely vulnerable (CEV) leukaemia patients, ensuring they have a voice.

9th July 2021

Lack of awareness of COVID-19 protection puts up to half a million at risk

Leukaemia Care is 1 of 16 health charities who is calling on the Government to do more to support around half a million people who are immunocompromised or immunosuppressed, and so may be less protected by the Covid-19 vaccine.

2nd July 2021

Booster jabs for the clinically extremely vulnerable – what does this mean for me?

The Joint Committee on Vaccines and Immunisations (JCVI) have published draft recommendations on the use of third vaccine doses as booster jabs. Here, we update you on what this means for blood cancer patients.

7th June 2021

The SMC recommends aclabrutinib to become a treatment option for certain groups of CLL patients in Scotland.

The Scottish Medicines Consortium (SMC) have today made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in Scotland.

25th May 2021

The latest from BSH

Here, we bring you the latest updates from the British Society of Haematology (BSH) conference.

23rd March 2021

Reflecting on the last year

Today is National Day of Reflection, in this article we look back on the last 12 months and showcase what we have achieved.

18th March 2021

Acalabrutinib to become a treatment option for certain groups of CLL patients in England

The National Institute for Health and Care Excellence (NICE) have made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in England.